• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12G filed by SQZ Biotechnologies Company

    1/4/24 4:15:33 PM ET
    $SQZ
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $SQZ alert in real time by email
    15-12G 1 d828700d1512g.htm 15-12G 15-12G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 15

     

     

    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

    UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

    OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934.

    Commission File Number 001-39662

     

     

    SQZ BIOTECHNOLOGIES COMPANY

    (Exact name of registrant as specified in its charter)

     

     

    PO Box 5515

    Wayland, MA 01778

    (617) 758-8672

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

    Common Stock, $0.001 par value per share

    (Title of each class of securities covered by this Form)

    None

    (Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

     

     

    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

     

    Rule 12g-4(a)(1)

      ☒

    Rule 12g-4(a)(2)

      ☐

    Rule 12h-3(b)(1)(i)

      ☐

    Rule 12h-3(b)(1)(ii)

      ☐

    Rule 15d-6

      ☒

    Rule 15d-22(b)

      ☐

    Approximate number of holders of record as of the certification or notice date: 51

    Pursuant to the requirements of the Securities Exchange Act of 1934 SQZ Biotechnologies Company has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

     

           SQZ BIOTECHNOLOGIES COMPANY
    Date:    January 4, 2024      By:   

    /s/ Howard Bernstein, M.D., Ph.D.

             Howard Bernstein, M.D., Ph.D.
             Interim Chief Executive Officer

     

     

     

    Get the next $SQZ alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SQZ

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SQZ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SQZ Biotechnologies to Consolidate Shares with 1-for-10 Reverse Stock Split

    Company Received Notice Regarding NYSE Continued Listing Standards Section 802.01B SQZ Biotechnologies Company (NYSE:SQZ) (the "Company" or "SQZ"), focused on unlocking the full potential of cell therapies, today announced that its Board of Directors (the "Board") has approved a 1-for-10 reverse stock split ("reverse split") of its common stock, par value $0.001 per share ("Common Stock"), that is expected to become effective on Thursday, July 6, 2023 at 5:00 p.m. Eastern Time (the "Effective Date"). The Company's common stock is expected to begin trading on a split-adjusted basis on the New York Stock Exchange ("NYSE") on July 7, 2023, under the existing symbol "SQZ" and new CUSIP number

    6/15/23 4:30:00 PM ET
    $SQZ
    Medicinal Chemicals and Botanical Products
    Health Care

    SQZ Biotechnologies Reports First Quarter 2023 Financial Results and Recent Portfolio Updates

    Phase 1 SQZ-AAC-HPV-101 Clinical Trial Resumed Following the Observation of a Confirmed Complete Response in the First Patient in the Lowest-Dose Cohort; Anticipate Data for the Highest-Dose Cohort in the Fourth Quarter of 2023 SQZ® eAPC Phase 1/2 Trial Enrollment on Track; Anticipate Data for the Highest-Dose Monotherapy Cohort in Mid-2023 SQZ Biotechnologies Company (NYSE:SQZ), focused on unlocking the full potential of cell therapies, today reported first quarter 2023 financial results and recent portfolio updates. "The confirmed complete response in our first patient in the AAC trial has brought enthusiasm to our trial sites, and we are encouraged by the positive momentum for e

    5/10/23 4:45:00 PM ET
    $SQZ
    Medicinal Chemicals and Botanical Products
    Health Care

    SQZ Biotechnologies Announces Confirmed Complete Response in HPV16+ Solid Tumor Patient in the Lowest-Dose Cohort of the SQZ-AAC-HPV-101 Clinical Trial

    A confirmed complete response was observed in the first patient in the lowest-dose cohort of the Phase 1 SQZ-AAC-HPV-101 clinical trial Following review and recommendation by the Study Safety Committee, the Company is advancing SQZ-AAC-HPV-101 trial to the highest-dose cohort Strong enrollment rates; Anticipate initial clinical data from the highest-dose cohort in the fourth quarter of 2023 SQZ Biotechnologies Company (NYSE:SQZ), focused on unlocking the full potential of cell therapies, today announced that, according to RECIST 1.1 criteria, a confirmed complete response was observed in the first patient in the lowest-dose cohort of the Phase 1 SQZ-AAC-HPV-101 clinical trial. The co

    3/22/23 4:50:00 PM ET
    $SQZ
    Medicinal Chemicals and Botanical Products
    Health Care

    $SQZ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Vink Patrick V.J.J.

    4 - SQZ Biotechnologies Co (0001604477) (Issuer)

    6/15/23 4:48:26 PM ET
    $SQZ
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 4 filed by Srivastava Sapna

    4 - SQZ Biotechnologies Co (0001604477) (Issuer)

    6/15/23 4:47:28 PM ET
    $SQZ
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 4 filed by Schulman Amy W

    4 - SQZ Biotechnologies Co (0001604477) (Issuer)

    6/15/23 4:46:40 PM ET
    $SQZ
    Medicinal Chemicals and Botanical Products
    Health Care

    $SQZ
    SEC Filings

    View All

    SEC Form DEFM14A filed by SQZ Biotechnologies Company

    DEFM14A - SQZ Biotechnologies Co (0001604477) (Filer)

    1/23/24 4:31:01 PM ET
    $SQZ
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form PREM14A filed by SQZ Biotechnologies Company

    PREM14A - SQZ Biotechnologies Co (0001604477) (Filer)

    1/12/24 8:57:36 AM ET
    $SQZ
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 15-12G filed by SQZ Biotechnologies Company

    15-12G - SQZ Biotechnologies Co (0001604477) (Filer)

    1/4/24 4:15:33 PM ET
    $SQZ
    Medicinal Chemicals and Botanical Products
    Health Care

    $SQZ
    Leadership Updates

    Live Leadership Updates

    View All

    SQZ Biotechnologies Announces Leadership Transition

    Chief Scientific Officer, Howard Bernstein, M.D., Ph.D., to Become Member of the Company's Board of Directors, Effective October 31, 2022 CSO Responsibilities to be Shared Among Ipsita Roymoulik, Ph.D., Scott Loughhead, Ph.D., and Maisam Dadgar as Senior Leaders of Chemistry, Manufacturing and Controls; Translational Research; and Engineering SQZ Biotechnologies Company (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that Howard Bernstein, M.D., Ph.D., has been appointed to the company's board of directors, effective October 31, 2022. Dr. Bernstein has served as the company's Chief Scientific Officer since July 2015, a

    9/6/22 4:30:00 PM ET
    $SQZ
    Medicinal Chemicals and Botanical Products
    Health Care

    SQZ Biotechnologies Appoints Micah Zajic as Chief Financial Officer

    Experienced Biotech Leader and Capital Markets Professional Elevated to Chief Financial Officer from Chief Business Officer Role Appointment Effective July 11, 2022 SQZ Biotechnologies (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that it has appointed Micah Zajic, as the company's Chief Financial Officer, effective immediately. Mr. Zajic has served as the company's Chief Business Officer since October 2020 and brings nearly 20 years of biotechnology and capital markets experience to the role. As CFO, Mr. Zajic will continue to report to the CEO and will lead the company's finance and accounting, business development,

    7/11/22 4:45:00 PM ET
    $SQZ
    Medicinal Chemicals and Botanical Products
    Health Care

    SQZ Biotechnologies Appoints Marshelle Smith Warren, M.D., as Chief Medical Officer

    Experienced Drug Developer Brings Over 25 Years of Clinical Development Industry Knowledge Across Oncology, Immunology, and Infectious Disease Appointment Effective June 1st, 2022 SQZ Biotechnologies (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that it has appointed Marshelle Smith Warren, M.D., as Chief Medical Officer. Dr. Warren will report to the CEO and lead the company's clinical development, clinical operations, translational medicine, and regulatory affairs functions. Marshelle has tremendous experience in cell-based therapeutic development and will provide complementary expertise as we seek to rapidly advan

    5/31/22 4:45:00 PM ET
    $SQZ
    Medicinal Chemicals and Botanical Products
    Health Care

    $SQZ
    Financials

    Live finance-specific insights

    View All

    SQZ Biotechnologies Announces Lead Cell Therapy Candidate Induced Radiographic, Symptomatic and Immune Response as Monotherapy in Post-Checkpoint HPV+ Solid Tumor Patient

    Patient's Clinical, Radiographic and Histologic Results Support Potential Impact of SQZ Investigational Therapeutic  Patient Demonstrated Symptomatic Improvement Radiographic Response Observed in Target Lesion Tumor Conversion from Desert to Inflamed Phenotype with 8-Fold Increase in CD8 T Cell Tumor Infiltration and 50-Fold Increase in Tumor PD-L1 Expression Interim Results from Ongoing Phase 1/2 Trial Showed Favorable Safety Data and Investigational Therapy was Generally Well Tolerated  Company to Host Conference Call Today at 8:00 a.m. ET SQZ Biotechnologies Company (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today presented

    12/9/21 6:10:00 AM ET
    $SQZ
    Medicinal Chemicals and Botanical Products
    Health Care

    SQZ Biotechnologies Lead Cell Therapy Candidate Generated Monotherapy Clinical Response Correlated with Substantial CD8 T Cell Tumor Infiltration in HPV+ Solid Tumor at Highest Dose

    Interim SQZ-PBMC-HPV Results from Ongoing Phase 1/2 Trial Showed Favorable Safety Data and that Therapy was Generally Well Tolerated Oral Presentation at ESMO Immuno-Oncology Congress on December 9 to Focus on Highest-Dose Monotherapy Cohort of SQZ™ APC Candidate Company to Host Conference Call on December 9 at 8:00 a.m. ET SQZ Biotechnologies Company (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced interim results from the highest-dose monotherapy cohort of its ongoing Phase 1/2 clinical trial of SQZ-PBMC-HPV, an investigational cell therapy being evaluated in certain patients with advanced or metastatic Human Papillomavirus

    12/2/21 6:15:00 AM ET
    $SQZ
    Medicinal Chemicals and Botanical Products
    Health Care

    $SQZ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by SQZ Biotechnologies Company (Amendment)

    SC 13G/A - SQZ Biotechnologies Co (0001604477) (Subject)

    2/13/24 5:13:06 PM ET
    $SQZ
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by SQZ Biotechnologies Company (Amendment)

    SC 13G/A - SQZ Biotechnologies Co (0001604477) (Subject)

    2/9/24 5:10:57 PM ET
    $SQZ
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by SQZ Biotechnologies Company (Amendment)

    SC 13G/A - SQZ Biotechnologies Co (0001604477) (Subject)

    2/14/23 2:25:08 PM ET
    $SQZ
    Medicinal Chemicals and Botanical Products
    Health Care